Curcumin and Piperine in Reducing Inflammation for Ureteral Stent-Induced Symptoms in Patients With Cancer

Inclusion Criteria:

Ureteral stent in place at study registration
Patient reports pain, spasms, or urgency symptoms after stent placement, which are thought to be unrelated to other causes as per the patient or healthcare provider or both (documentation in the medical record is unnecessary)
Ability to complete English language questionnaires by themselves or with assistance
After the week-long study treatment, participants must be willing to return to the enrolling institution for a follow-up visit
Willingness to provide mandatory 24 hour urine collection samples for research purposes
Able to swallow supplements
Patient must have either a history of cancer or active cancer
Registration >= 7 days after placement of a new stent or >= 3 days after a stent exchange
Willingness to refrain from grapefruit juice for 7 days prior to and for 7 days during the study

Exclusion Criteria:

Receiving warfarin at registration
Active cholecystitis
Requires treatment with non-steroidal anti-inflammatory agents that cannot be stopped for one week during study participation
Taking any of the following drugs at the time of study participation: epidermal growth factor receptor inhibitor, topoisomerase 1 inhibitor (camptothecin, irinotecan); buspirone, benzodiazepines, zolpidem, calcium channel blockers (such as felodipine, nifedipine, verapamil); digoxin or quinidine; codeine or fentanyl; phenytoin, propranolol, rifampin, or theophylline
History of alcohol abuse